SABCS 2023 (English): Breast Cancer Pro Portal

View Session

New Drug Approvals for Metastatic Breast Cancer in 2023

Kate Lathrop, MD

17:08 Minutes

View Session

GS01-06 - Advancing evidence of the associations between specific benign breast diagnoses and future breast cancer risk

Hope Rugo, MD

6:55 Minutes

View Session

GS01-02 - Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2 - breast cancer: KEYNOTE-756

Hope Rugo, MD

12:45 Minutes

View Session

GS01-03 - Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy:interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial.

Hope Rugo, MD

8:14 Minutes

View Session

GS01-08 - CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer

Hope Rugo, MD

5:54 Minutes

View Session

GS01-01 - Biomarker results in high-risk estrogen receptor positive, human epidermal growth factor receptor 2 negative primary breast cancer following neoadjuvant chemotherapy ± nivolumab: An exploratory analysis of CheckMate 7FL

Hope Rugo, MD

10:47 Minutes

View Session

RF01-06 - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer

Ruth O'Regan, MD

Minutes

View Session

RF01-07 - The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC

Ruth O'Regan, MD

Minutes

View Session

RF01-02 - A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy

Ruth O'Regan, MD

Minutes

View Session

RF01-08 - A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE)

Ruth O'Regan, MD

05:12 Minutes

View Session

RF01-03 - PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs letrozole and palbociclib in the PARSIFAL study

Ruth O'Regan, MD

Minutes

View Session

GS01-05 - Pembrolizumab + olaparib vs pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy for locally recurrent inoperable or metastatic TNBC: Randomized open-label phase 2 KEYLYNK-009 study

Hope Rugo, MD

9:56 Minutes

View Session

GS01-10 - HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated her2-positive metastatic breast cancer

Hope Rugo, MD

8:58 Minutes

View Session

GS01-12 - MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer

Hope Rugo, MD

8:09 Minutes

View Session

RF01-01 - SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary cancer

Ruth O'Regan, MD

4:46 Minutes

View Session

RF01-04 - Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification

Ruth O'Regan, MD

Minutes

View Session

GS02-04 - Surgical treatment of women with breast cancer and a BRCA1 mutation: an international analysis of the impact of bilateral mastectomy on survival.

Adam Brufsky, MD, PhD

Minutes

View Session

GS02-06 - Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial.

Adam Brufsky, MD, PhD

Minutes

View Session

GS02-08 - Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer

Adam Brufsky, MD, PhD

Minutes

View Session

GS02-07 - Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG Oncology/NSABP B-51/RTOG 1304

Adam Brufsky, MD, PhD

Minutes

View Session

GS02-01 - Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01.

Adam Brufsky, MD, PhD

Minutes

View Session

LBO1-03 - Randomized Phase II Study of Neoadjuvant Nivolumab (N) 2 week lead-in followed by 12 weeks of concurrent N+carboplatin plus paclitaxel (CbP) vs concurrent N+CbP in Triple Negative Breast Cancer (TNBC): (BCT1902/IBCSG 61-20 Neo-N)

Kevin Kalinsky, MD, MS

Minutes

View Session

GS03-01- Magnetic Resonance Imaging and a 12-gene expression assay to optimize local therapy for ductal carcinoma in situ: 5-year clinical outcomes of E4112

Joseph Sparano, MD, Tisch Cancer Institute, Mt. Sinai

Minutes

View Session

GS03-03 - Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial

Joseph Sparano, MD, Tisch Cancer Institute, Mt. Sinai

Minutes

View Session

GS03-06 - Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial

Joseph Sparano, MD, Tisch Cancer Institute, Mt. Sinai

Minutes

View Session

GS03-12 - Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis

Kevin Kalinsky, MD, MS

Minutes

View Session

LBO1-02 - Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial

Kevin Kalinsky, MD, MS

Minutes

View Session

LBO1-04 - Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)

Kevin Kalinsky, MD, MS

Minutes

View Session

LBO1-01 - Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study

Minutes

View Session

GS03-13 - Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis

Kevin Kalinsky, MD, MS

Minutes

View Session

GS03-07 - Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer.

Joseph Sparano, MD, Tisch Cancer Institute, Mt. Sinai

Minutes

View Session

Metastatic Breast Cancer

Viriginia Kaklamani, MD, DSc

Minutes

View Session

Early Breast Cancer

Viriginia Kaklamani, MD, DSc

Minutes

SABCS 2023 Video highlights